ABTAbbott Laboratories
- Next report
- No date yet
- none in the next 8 weeks
- Last result
- $1.42In line
- vs $1.43 expected on Oct 21
- Stock move on it
- −1.89%
- one session
- Typical move
- ±6.3%
- average over 2 reports
- Price
- $107.28
- −1.84% today · $174B cap
Past and upcoming reports
2
| Oct 21, 2026 | Sep 30, 2026 | Time not given | $1.43 | $1.42 | −1.89% |
| Jul 16, 2026 | Jun 30, 2026 | Time not given | $1.28 | Missed$1.26 | +10.71% |
After the report
Jul 16, 2026 report
This covers the Jul 16, 2026 report. The Oct 21, 2026 numbers are in the table above.
Abbott misses Q2 EPS by 1.6%, stock rises 1.9%
Abbott reported Q2 EPS of $1.26, missing the $1.28 consensus by 1.6%. Despite the miss, the stock rose 1.87% on the day, suggesting the market is focusing on forward guidance or other positive factors. The company's growth metrics remain weak, but valuation appears attractive relative to the sector.
Reported against expected
MissedReported EPS $1.26 vs estimate $1.28, a miss of -1.56%.
Guidance
Not explicitly provided in payload. stock rose 1.87% on the day, suggesting positive forward outlook.
How the stock reacted
Stock closed at $100.68, up 1.87% from previous close of $98.83 on volume of 17.1M shares.
What changed
EPS miss of 1.6% vs consensus, but stock rallied 1.87%.
What the price now assumes
Market pricing a positive outlook despite the miss, supported by price action.
What it means for the business
Upgrade bias if forward guidance confirms growth. watch next quarter's revenue.
The next one to three months, as we saw it then
Better case30%
Strong forward guidance and operational momentum drive re-rating toward analyst target of $119.
Base case50%
Stock trades in a range between $95 and $110 as market digests mixed signals.
Worse case20%
The EPS miss signals underlying weakness, and the stock retraces to test $92 low.
If you hold it
Hold unless next-quarter revenue misses guidance materially or customer concentration risk worsens.
If you are watching
Add only if next-quarter guidance is reiterated or raised. avoid if guidance is cut or geopolitical risk escalates.
Scenario odds are a judgement, not measured.